HRP20010700B1 - Prezelatinizirani skrob u formulaciji s kontroliranim otpustanjem - Google Patents

Prezelatinizirani skrob u formulaciji s kontroliranim otpustanjem

Info

Publication number
HRP20010700B1
HRP20010700B1 HR20010700A HRP20010700A HRP20010700B1 HR P20010700 B1 HRP20010700 B1 HR P20010700B1 HR 20010700 A HR20010700 A HR 20010700A HR P20010700 A HRP20010700 A HR P20010700A HR P20010700 B1 HRP20010700 B1 HR P20010700B1
Authority
HR
Croatia
Prior art keywords
controlled release
starch
preelatinized
release formulation
formulation
Prior art date
Application number
HR20010700A
Other languages
English (en)
Croatian (hr)
Inventor
Petrus Gerebern Vandecruys Roger
Marie Jozef Jans Eugene
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20010700(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20010700A2 publication Critical patent/HRP20010700A2/hr
Publication of HRP20010700B1 publication Critical patent/HRP20010700B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HR20010700A 1999-03-31 2000-03-24 Prezelatinizirani skrob u formulaciji s kontroliranim otpustanjem HRP20010700B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201018 1999-03-31
PCT/EP2000/002620 WO2000059477A1 (en) 1999-03-31 2000-03-24 Pregelatinized starch in a controlled release formulation

Publications (2)

Publication Number Publication Date
HRP20010700A2 HRP20010700A2 (en) 2003-04-30
HRP20010700B1 true HRP20010700B1 (hr) 2011-01-31

Family

ID=8240051

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010700A HRP20010700B1 (hr) 1999-03-31 2000-03-24 Prezelatinizirani skrob u formulaciji s kontroliranim otpustanjem

Country Status (27)

Country Link
US (3) US6667060B1 (cs)
EP (3) EP1169024B1 (cs)
JP (2) JP4928668B2 (cs)
KR (3) KR20100036398A (cs)
CN (1) CN1208090C (cs)
AT (1) ATE313319T1 (cs)
AU (1) AU776645B2 (cs)
BG (3) BG65470B1 (cs)
BR (1) BR0009437A (cs)
CA (1) CA2371940C (cs)
CZ (2) CZ300551B6 (cs)
DE (1) DE60024981T2 (cs)
DK (1) DK1169024T3 (cs)
EA (2) EA005291B1 (cs)
EE (1) EE05022B1 (cs)
ES (2) ES2255490T3 (cs)
HK (1) HK1044715B (cs)
HR (1) HRP20010700B1 (cs)
HU (1) HU230440B1 (cs)
IL (3) IL145661A0 (cs)
MX (1) MX339071B (cs)
NO (2) NO332167B1 (cs)
NZ (1) NZ514890A (cs)
PL (1) PL198797B1 (cs)
SI (1) SI1169024T1 (cs)
SK (1) SK288541B6 (cs)
WO (1) WO2000059477A1 (cs)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514890A (en) * 1999-03-31 2003-05-30 Janssen Pharmaceutica Nv Pregelatinized starch in a controlled release formulation
CA2428971A1 (en) * 2000-11-14 2003-05-01 New River Pharmaceuticals Inc. Conjugates of a therapeutic agent and a peptide carrier
US20110092677A1 (en) * 2001-08-30 2011-04-21 Biorexis Technology, Inc. Modified transferin-antibody fusion proteins
US8663687B2 (en) * 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US7425292B2 (en) * 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
EP1443917B1 (en) * 2001-11-07 2006-03-29 Synthon B.V. Tamsulosin tablets
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
WO2003103634A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US8679533B2 (en) * 2002-07-25 2014-03-25 Pharmacia Corporation Pramipexole once-daily dosage form
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
AR040683A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida que comprende un agonista de los receptores de la dopamina
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AU2003256844A1 (en) * 2002-07-29 2004-02-16 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
AU2007254665B2 (en) * 2002-07-29 2010-08-19 Alza Corporation Methods and dosage forms for controlled delivery and paliperidone
WO2004037234A2 (en) * 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004054550A1 (en) * 2002-12-16 2004-07-01 Ranbaxy Laboratories Limited An extended release pharmaceutical composition of phenytoin sodium
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060105036A1 (en) * 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
EP2535042A1 (en) * 2003-06-16 2012-12-19 ANDRX Pharmaceuticals LLC. Oral sustained-release composition comprising a macrolide
CN1823091B (zh) 2003-07-11 2010-05-12 旭化成化学株式会社 功能性淀粉粉末
TWI366442B (en) * 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
ATE551339T1 (de) 2003-11-05 2012-04-15 Sarcode Bioscience Inc Modulatoren der zellulären adhäsion
WO2005087198A1 (en) * 2004-03-10 2005-09-22 Ranbaxy Laboratories Limited Processes for the preparation of solid dosage forms of amorphous valganciclovir hydrochloride
US20080234353A1 (en) * 2004-03-24 2008-09-25 Reynir Eyjolfsson Formulations of Ramipril
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
EP1591107A1 (en) * 2004-04-28 2005-11-02 Pfizer GmbH Arzneimittelwerk Gödecke Process for the selective increase of a release rate of an active material from a pharmaceutical composition
CA2564994A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
ES2355735T5 (es) * 2004-08-13 2014-06-27 Boehringer Ingelheim International Gmbh Formulación en comprimidos de liberación extendida que contiene pramipexol o una de sus sales farmac�uticamente aceptables, método para su fabricación y su uso
AU2005271193B2 (en) * 2004-08-13 2011-11-24 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
SI1803447T1 (sl) * 2004-09-09 2010-01-29 Psicofarma S A De C V Farmacevtski sestavek za zadrĺ˝evano sproĺ äśanje hidralazina in njegova uporaba kot podrpora zdravljenju raka
AU2005304664A1 (en) * 2004-11-05 2006-05-18 King Pharmaceuticals Research & Development, Inc. Stabilized ramipril compositions and methods of making
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US20060121108A1 (en) * 2004-12-02 2006-06-08 Prasad C K System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
WO2006070930A1 (en) 2004-12-27 2006-07-06 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
JP5739080B2 (ja) * 2005-01-27 2015-06-24 アレムビック・リミテッドＡｌｅｍｂｉｃ Ｌｉｍｉｔｅｄ レベチラセタムの徐放性製剤
KR101213345B1 (ko) * 2005-04-28 2012-12-17 에자이 알앤드디 매니지먼트 가부시키가이샤 항치매약을 함유하는 조성물
AU2006247136C1 (en) 2005-05-17 2020-01-16 Bausch + Lomb Ireland Limited Compositions and methods for treatment of eye disorders
ES2408687T3 (es) * 2005-05-26 2013-06-21 Dainippon Sumitomo Pharma Co., Ltd. Composición farmacéutica que contiene lurasidona
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US8252776B2 (en) * 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
DE102005033943A1 (de) * 2005-07-20 2007-02-22 Hexal Ag Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für ein Neuroleptikum
JPWO2007018190A1 (ja) * 2005-08-10 2009-02-19 塩野義製薬株式会社 苦味抑制製剤
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
DE102006003512A1 (de) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
RS51647B (sr) 2006-10-18 2011-10-31 Pfizer Products Inc. Jedinjenja biaril etar uree
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
JP5183733B2 (ja) * 2007-05-23 2013-04-17 フイルメニツヒ ソシエテ アノニム フレーバー組成物
US20080292683A1 (en) * 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
KR20100020459A (ko) 2007-06-08 2010-02-22 아드레넥스 파마슈티컬스, 아이엔씨. 지연 방출형 제제 및 아드레날린 조절부전의 치료방법
BRPI0811732A2 (pt) * 2007-06-08 2014-11-18 Boehring Ingelheim Internat Gmbh Formulação de liberação prolongada de nevirapina
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US20090081294A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained release dosage form for lubricating an oral cavity
US20090081291A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User
CA2678092C (en) * 2007-10-16 2013-07-30 Labopharm Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
WO2009054914A1 (en) 2007-10-19 2009-04-30 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
WO2009076764A1 (en) 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
WO2009139817A2 (en) * 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2013205004B2 (en) * 2008-06-30 2015-08-27 Tocagen Inc. Formulations of 5-fluorocytosine and Uses Thereof
WO2010002937A1 (en) * 2008-06-30 2010-01-07 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
KR101612146B1 (ko) * 2008-07-16 2016-04-12 리히터 게데온 닐트. 도파민 수용체 리간드를 함유하는 약학적 제형
WO2010011712A1 (en) * 2008-07-22 2010-01-28 General Mills, Inc. Fruit products containing omega-3 fatty acids
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US20100040727A1 (en) * 2008-08-18 2010-02-18 Monosol Rx, Llc Method for Improving Uniformity of Content in Edible Film Manufacturing
JP2012508713A (ja) * 2008-11-17 2012-04-12 ビーエーエスエフ ソシエタス・ヨーロピア デンプン含有顆粒製剤
US8282954B2 (en) * 2008-12-15 2012-10-09 Monosol Rx, Llc Method for manufacturing edible film
ES2509497T3 (es) 2008-12-16 2014-10-17 Paladin Labs Inc. Formulación de liberación controlada para evitar un uso indebido
JP5723787B2 (ja) 2009-01-23 2015-05-27 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 制御放出の製剤処方または食品処方およびその製造方法
EP3045043B1 (en) 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
US20100285130A1 (en) * 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
MX340134B (es) 2009-07-09 2016-06-28 Oshadi Drug Administration Ltd Composiciones portadoras de matriz, métodos y usos.
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN102753196A (zh) * 2009-12-10 2012-10-24 莫诺索尔克斯有限公司 口服薄膜条内掩味的pH敏感性化合物
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
CA2784587A1 (en) * 2009-12-28 2011-07-28 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
MX2012009798A (es) * 2010-02-24 2012-09-12 Pfizer Composiciones veterinarias.
US8975387B1 (en) 2010-03-22 2015-03-10 North Carolina State University Modified carbohydrate-chitosan compounds, methods of making the same and methods of using the same
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
EP2730274B1 (en) * 2010-12-21 2015-08-05 Akzo Nobel Chemicals International B.V. Instant powders for aqueous cosmetic and pharmaceutical applications
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
JP5960523B2 (ja) * 2012-06-29 2016-08-02 旭化成株式会社 加工澱粉と溶出制御剤からなる固形製剤
BR112015001608B1 (pt) 2012-07-25 2022-08-23 Novartis Ag Métodos para purificação e síntese de um composto inibidor lfa-1, mistura reacional e composições compreendendo o dito composto e composto isolado inibidor lfa-1
CN104487048A (zh) * 2012-07-27 2015-04-01 大正制药株式会社 外用剂组合物
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EA201690732A1 (ru) 2013-10-10 2016-12-30 Синерджи Фармасьютикалз, Инк. Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций
US9561187B1 (en) * 2014-02-03 2017-02-07 CMAX Technologies, Inc. Sustained release metoprolol formulations
EP3122754A4 (en) * 2014-03-26 2018-02-21 Canget Biotekpharma, LLC Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease
CN103948550A (zh) * 2014-04-22 2014-07-30 青岛市市立医院 一种西沙必利分散片及其制备方法
EP3149050A1 (en) 2014-06-02 2017-04-05 Tethis, Inc. Modified biopolymers and methods of producing and using the same
BE1021194B1 (nl) * 2014-07-07 2015-07-14 Nordic Specialty Pharma Bvba Paracetamol tabletten
EP3380577A4 (en) 2015-11-23 2019-04-17 Tethis, Inc. COATED PARTICLES AND METHODS OF PRODUCTION AND USE
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CA3022840A1 (en) 2016-05-05 2017-11-09 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
CN107198680A (zh) * 2016-10-12 2017-09-26 钟术光 缓释制剂
JP7426685B2 (ja) * 2018-06-14 2024-02-02 株式会社東洋新薬 錠剤
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
GB2606585B (en) * 2021-03-31 2024-02-14 Tate & Lyle Solutions Usa Llc Pregelatinized inhibited hollow starch products and methods of making and using them
EP4422607A4 (en) 2021-10-25 2025-09-03 Aquestive Therapeutics Inc ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2195893A (en) * 1986-10-09 1988-04-20 Sandoz Ltd Sustained release composition
EP0280613A1 (fr) * 1987-02-18 1988-08-31 Pierre Fabre Medicament Comprimé de dihydroergotamine (D.H.E.) du type à matrice hydrophile et son procédé de fabrication
EP0299877A1 (fr) * 1987-07-16 1989-01-18 Pierre Fabre Medicament Comprimés de type à matrice hydrophile à base de salbutamol et leur procédé de préparation
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5635208A (en) * 1993-07-20 1997-06-03 Mcneil-Ppc, Inc. Granulation process for producing an acetaminophen and diphenhydramine hydrochloride composition and composition produced by same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
JPS615027A (ja) * 1984-06-18 1986-01-10 Sadahiro Nakano 徐放性固形製剤
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
FR2666506A1 (fr) 1990-09-07 1992-03-13 Pf Medicament Comprime a liberation prolongee a base de 5-mononitrate d'isosorbide et son procede de preparation.
EP0686034B1 (en) * 1993-02-26 2001-06-13 The Procter & Gamble Company Bisacodyl dosage form
US5698226A (en) 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
TW349870B (en) 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
JPH07204796A (ja) * 1994-01-14 1995-08-08 Kawasaki Steel Corp 金属薄帯の製造装置
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
ZA959221B (en) 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
ATE352289T1 (de) * 1995-05-02 2007-02-15 Taisho Pharmaceutical Co Ltd Mittel zur oralen verabreichung
JPH0952832A (ja) * 1995-08-10 1997-02-25 Takeda Chem Ind Ltd 医薬組成物
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
PT869772E (pt) 1995-12-27 2002-03-28 Janssen Pharmaceutica Nv Forma galenica solida bioadesiva
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
RU2227137C2 (ru) * 1998-09-26 2004-04-20 Авентис Фарма Дойчланд Гмбх СПОСОБ ПОЛУЧЕНИЯ α, α-ДИМЕТИЛФЕНИЛУКСУСНОЙ КИСЛОТЫ ИЗ α, α-ДИМЕТИЛБЕНЗИЛЦИАНИДА БЕЗ ДАВЛЕНИЯ
NZ514890A (en) 1999-03-31 2003-05-30 Janssen Pharmaceutica Nv Pregelatinized starch in a controlled release formulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2195893A (en) * 1986-10-09 1988-04-20 Sandoz Ltd Sustained release composition
EP0280613A1 (fr) * 1987-02-18 1988-08-31 Pierre Fabre Medicament Comprimé de dihydroergotamine (D.H.E.) du type à matrice hydrophile et son procédé de fabrication
EP0299877A1 (fr) * 1987-07-16 1989-01-18 Pierre Fabre Medicament Comprimés de type à matrice hydrophile à base de salbutamol et leur procédé de préparation
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5635208A (en) * 1993-07-20 1997-06-03 Mcneil-Ppc, Inc. Granulation process for producing an acetaminophen and diphenhydramine hydrochloride composition and composition produced by same
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use

Also Published As

Publication number Publication date
ES2255490T3 (es) 2006-07-01
BG105857A (en) 2002-04-30
EA200401009A1 (ru) 2004-12-30
EP1649851A3 (en) 2008-04-23
IL145661A (en) 2013-10-31
CA2371940A1 (en) 2000-10-12
DK1169024T3 (da) 2006-05-08
KR20060097068A (ko) 2006-09-13
EE05022B1 (et) 2008-06-16
MX339071B (es) 2016-05-09
MXPA01009877A (es) 2002-05-06
BG110060A (bg) 2008-12-30
EA005291B1 (ru) 2004-12-30
NO20111249L (no) 2001-09-28
HUP0200611A3 (en) 2003-04-28
CZ300551B6 (cs) 2009-06-17
CN1345233A (zh) 2002-04-17
ES2688273T3 (es) 2018-10-31
SK13542001A3 (sk) 2002-08-06
EP1169024A1 (en) 2002-01-09
HK1044715A1 (en) 2002-11-01
EA200101026A1 (ru) 2002-06-27
ATE313319T1 (de) 2006-01-15
NO332167B1 (no) 2012-07-09
NO342239B1 (no) 2018-04-23
US8591945B2 (en) 2013-11-26
IL219820A0 (en) 2012-06-28
HRP20010700A2 (en) 2003-04-30
BR0009437A (pt) 2002-01-15
AU776645B2 (en) 2004-09-16
BG66095B1 (bg) 2011-04-29
NZ514890A (en) 2003-05-30
NO20014724L (no) 2001-09-28
SK288541B6 (sk) 2018-03-05
EP1611881A1 (en) 2006-01-04
HU230440B1 (hu) 2016-06-28
PL355096A1 (en) 2004-03-22
AU3963800A (en) 2000-10-23
JP2011006485A (ja) 2011-01-13
JP4928668B2 (ja) 2012-05-09
CZ20013375A3 (cs) 2002-05-15
US20040062805A1 (en) 2004-04-01
BG65470B1 (bg) 2008-09-30
HK1044715B (zh) 2006-02-17
HUP0200611A2 (hu) 2002-07-29
WO2000059477A1 (en) 2000-10-12
JP2002541090A (ja) 2002-12-03
EE200100505A (et) 2002-12-16
EP1649851A2 (en) 2006-04-26
DE60024981T2 (de) 2006-09-14
US20090191266A1 (en) 2009-07-30
EP1649851B1 (en) 2018-06-20
EP1169024B1 (en) 2005-12-21
PL198797B1 (pl) 2008-07-31
CA2371940C (en) 2008-07-15
KR20020002384A (ko) 2002-01-09
SI1169024T1 (sl) 2006-06-30
KR100660594B1 (ko) 2006-12-22
CZ2006443A3 (cs) 2019-02-20
DE60024981D1 (de) 2006-01-26
CN1208090C (zh) 2005-06-29
IL145661A0 (en) 2002-06-30
CZ307700B6 (cs) 2019-02-20
NO20014724D0 (no) 2001-09-28
KR20100036398A (ko) 2010-04-07
US6667060B1 (en) 2003-12-23

Similar Documents

Publication Publication Date Title
HRP20010700B1 (hr) Prezelatinizirani skrob u formulaciji s kontroliranim otpustanjem
ES2095818T1 (es) Composicion cosmetica y/o dermatologica de soporte hidrofilo y vitamina c mezclables extemporaneamente.
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
HRP20010463B1 (hr) Smjesa s kontroliranim otpuštanjem koja sadrži galantamin
BR0114782A (pt) Composição de copolìmero, processo para preparar a mesma, composição aquosa, produtos, composição contendo agente terapêutico, composição de eletrólito e uso da composição de copolìmero
ES2180574T3 (es) Formulaciones de liberacion controlada de oxibutinina.
MXPA97002401A (es) Agente antiinflamatorio para uso externo.
NO20016108D0 (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
BR0007147A (pt) Composição de tensìdio contendo tensìdio gemini e co-anfifila, sua preparação e aplicação
MX9502035A (es) Utilizacion de los compuestos antifungicos y de los compuestos antibacterianos halogenados para la obtencion de composiciones cosmeticas para disminuir o evitar la caida del cabello.
BR9801652A (pt) Resorcinil-triazinas
CA2105487A1 (en) Antiviral nucleoside combination
NO971192D0 (no) Fremgangsmåter for avlevering av materialer inn i huden, og sammensetninger som blir anvendt
NO934394L (no) Haarpleiemidler og blandinger inneholdende hydrofobe haarpleiepolymerer
DE69403656D1 (de) Stabile, orale und absorbierbare therapeutische zusammensetzungen von nadh und nadph
NO993028D0 (no) Vannbaserte alkoholhydroksykarboksylperoksid-sammensetninger, fremstilling og anvendelse herav
ATE363267T1 (de) Mittel zur verbesserung der hauttextur
ES2159403T3 (es) Poliuretanos termoplasticos que contienen principios activos.
AU2003285327A1 (en) Cosmetic dressings containing a waxy component, a film-forming agent and a gel-forming substance
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
AU5980200A (en) Ophthalmic compositions in form of aqueous gels
SE0001916D0 (sv) Novel formulation
AU5487101A (en) Cosmetic or dermatological product comprising a freeze-dried hydrocolloid composition
PT928192E (pt) Gel antimicotico com elevada libertacao de principio activo

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190218

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20200324